Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

venBio Partners

Investor type Private Equity Firm
Founders Corey Goodman Kurt von Emster Robert Adelman


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 70
Average round size
The average size of a deal this fund participated in
Portfolio companies 45
Rounds per year 5.38
Lead investments 18
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 23
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Biopharma

The venture was found in North America in United States. The leading representative office of defined VC is situated in the San Francisco.

We can highlight the next thriving fund investment areas, such as Genetics, Therapeutics. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Adaptimmune, Harmony Biosciences, Checkmate Pharmaceuticals. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.

The current fund was established by Corey Goodman, Kurt von Emster, Robert Adelman. The overall number of key employees were 1.

The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 18 percentage points more often commits exit comparing to other companies. Opposing the other organizations, this venBio Partners works on 12 percentage points more the average amount of lead investments. The top activity for fund was in 2018. The common things for fund are deals in the range of 50 - 100 millions dollars. The average startup value when the investment from venBio Partners is 100-500 millions dollars. The top amount of exits for fund were in 2019.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the venBio Partners, startups are often financed by Remeditex Ventures, Sofinnova Investments, F-Prime Capital. The meaningful sponsors for the fund in investment in the same round are Vivo Capital, F-Prime Capital, Sofinnova Investments. In the next rounds fund is usually obtained by Vivo Capital, F-Prime Capital, Cormorant Asset Management.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of venBio Partners:
Typical Co-investors
venBio Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after venBio Partners:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
1440 Foundation California, Saratoga, United States
AARD Capital -
Accelerator Fund Pennsylvania, Pittsburgh, United States
Activa Capital France, Ile-de-France, Paris
BOOST Programs France, Ile-de-France, Paris
Bucketplace -
eSeed Ventures -
Formula Ventures Israel, Tel Aviv, Tel Aviv District
Green Arrow Capital Italy, Lombardy, Milan
Hongfei Zichan China, Chongming, Chongming District
Kitano Investments -
KoppiCatch Finland, Helsinki, Southern Finland
Legion Capital Cheyenne, United States, Wyoming
Powerhouse Ventures California, Oakland, United States
PYJ-Dynasty Venture Fund California, Santa Barbara, United States
Relan Global Management LLC California, Los Gatos, United States
Rho Ventures New York, New York, United States
Shoutou Zichan China, Guangdong, Zhuhai
Yamaguchi Technology Licensing Organization Japan, Tokyo

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Entact Bio

Life Science
$81M06 Dec 2022 Watertown, Massachusetts, United States

Fog Pharmaceuticals

Health Care
$178M21 Nov 2022 Cambridge, Massachusetts, United States


Health Care
$300M13 Sep 2022 Los Angeles, California, United States


Life Science
$111M20 Jan 2022 California, United States


$75M19 Jan 2022 New Jersey, United States

NorthSea Therapeutics

Health Care
$80M17 Dec 2021 The Netherlands, North Holland, Netherlands

Ablaze Pharmaceuticals

$75M29 Nov 2021 Jingan, Shanghai, China


Health Care
$250M16 Nov 2021 Los Angeles, California, United States


Artificial Intelligence
Health Care
Life Science
$32M19 Oct 2021 New York, New York, United States
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

Ventyx Biosciences Raises $114M in Funding

– Ventyx is an Encinitas, California-based clinical-stage biotechnology company advancing a broad pipeline of potent and selective small-molecule drug candidates to treat inflammatory diseases and autoimmune disorders.
– The company raised $114m in Series C funding.
– The round was led by venBio Partners alongside new investors, including Third Point, RTW Investments, LP, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital (a Citadel company), Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA, Cormorant Asset Management, and participation from founding investor New Science Ventures.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent venBio Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: